Premium
Impact of hepatitis E virus testing on the safety of blood components in Germany – results of a simulation study
Author(s) -
Kamp Christel,
Blümel Johannes,
Baylis Sally A.,
BekeredjianDing Isabelle,
Chudy Michael,
Heiden Margarethe,
Henseler Olaf,
KellerStanislawski Brigitte,
de Vos Anneke S.,
Funk Markus B.
Publication year - 2018
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12719
Subject(s) - medicine , hepatitis e virus , blood transfusion , virology , epidemiology , hepatitis c virus , virus , immunology , biology , genotype , biochemistry , gene
Hepatitis E virus (HEV) infections may be acquired through transfusion of blood components. As transfusion‐transmitted infections mostly affect vulnerable individuals, measures to ensure the supply of safe blood components are under discussion. On the basis of the epidemiological situation in Germany, different testing strategy scenarios were investigated through simulation studies. Testing for HEV RNA by nucleic acid amplification technique (NAT) assays with a pool size of 96, and a 95% LoD of 20 IU/ml will result in an 80% reduction in expected HEV transmissions as well as of consequent chronic infections with subsequent severe complications.